Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 4,654Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) ResearchPulmonary Hypertension Research and Treatments

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

Open access
Richeldi, Luca, du Bois, Roland M., Raghu, Ganesh, Azuma, Arata, Brown, Kevin K., Costabel, Ulrich, Cottin, Vincent, Flaherty, Kevin R., Hansell, David M., Inoue, Yoshikazu, Kim, Dong Soon, Kolb, Martin, Nicholson, Andrew G., Noble, Paul W., Selman, Moisés, Taniguchi, Hiroyuki, Brun, Michèle, Le Maulf, Florence, Girard, Mannaïg, Stowasser, Susanne, Schlenker-Herceg, Rozsa, Disse, Bernd, Collard, Harold R.·2014·New England Journal of Medicine

Abstract

BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).

Overview

CoChat Summary

TL;DR

This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.

Key findings

  • In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
  • In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
  • For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
  • The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.

Methods

  • Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
  • 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
  • Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.

Limitations

  • The text does not state formal study limitations.
  • Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
  • Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1402584

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations

5 more claims

Create a free account to see all 12 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 1
  • Probably not a substantial claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

8 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 21 references

Cited by

See all 4,654

Metadata

Authors
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
Affiliations
  • NIHR Southampton Respiratory Biomedical Research Unit (GB)
  • University of Washington (US)
  • Nippon Medical School (JP)
  • Ruhrlandklinik (DE)
  • Université de Lyon (FR)
  • Michigan Medicine (US)
  • Royal Brompton & Harefield NHS Foundation Trust (GB)
  • NHO Kinki Chuo Chest Medical Center (JP)
  • Asan Medical Center (KR)
  • McMaster University (CA)
  • Cedars-Sinai Medical Center (US)
  • Instituto Nacional de Enfermedades Respiratorias (MX)
  • Tosei General Hospital (JP)
  • Boehringer Ingelheim (Germany) (DE)
  • University of California, San Francisco (US)
Venue
New England Journal of Medicine
Published
2014-05-29
Volume
370
Issue
22
Pages
2071-2082
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2138871107
Cited by
4,654
References
21
Citations by year
2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
FWCI
263.74
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
  • Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
  • Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
  • Digital Access to Libraries (submittedVersion)
  • ePrints Soton (University of Southampton) (submittedVersion)
  • IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
  • VUBIR (Vrije Universiteit Brussel) (submittedVersion)
  • Padua Research Archive (University of Padova) (submittedVersion)
Funders
  • Amgen
  • Pfizer
  • GlaxoSmithKline
  • Sanofi
  • Gilead Sciences
  • Biogen
  • Celgene
  • FibroGen
  • Ikaria
  • University Hospital Southampton NHS Foundation Trust
  • Massachusetts Medical Society
  • Royal Brompton and Harefield NHS Foundation Trust
  • Galecto
  • Veracyte
  • National Institute for Health and Care Research (NF-SI-0512-10157)
  • Imperial College London
  • Shionogi
  • Genentech
  • Japan Society for the Promotion of Science (24591149)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Keywords
nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
MeSH terms
Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. https://app.cochat.ai/papers/10.1056/nejmoa1402584
The paper
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., . . . Collard, H. R. (2014). Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1402584

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.